About: Amoxicillin for acute lower respiratory tract infection in primary care: subgroup analysis by bacterial and viral aetiology

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Amoxicillin for acute lower respiratory tract infection in primary care: subgroup analysis by bacterial and viral aetiology Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Amoxicillin for acute lower respiratory tract infection in primary care: subgroup analysis by bacterial and viral aetiology
Source	Elsevier; Medline; PMC
abstract	OBJECTIVE: We aimed to assess the effects of amoxicillin treatment in adult patients presenting to primary care with a lower respiratory tract infection (LRTI) who were infected with a potential bacterial, viral, or mixed bacterial/viral infection. METHODS: This multicentre randomized controlled trial focused on adults with LRTI not suspected for pneumonia. Patients were randomized to receive either antibiotic (amoxicillin 1 g) or placebo three times daily for 7 consecutive days using computer-generated random numbers (follow-up 28 days). In this secondary analysis of the trial, symptom duration (primary outcome), symptom severity (scored 0–6), and illness deterioration (reconsultation with new or worsening symptoms, or hospital admission) were analysed in pre-specified subgroups using regression models. Subgroups of interest were patients with a (strictly) bacterial, (strictly) viral, or combined infection, and patients with elevated values of procalcitonin, C-reactive protein, or blood urea nitrogen. RESULTS: 2058 patients (amoxicillin n = 1036; placebo n = 1022) were randomized. Treatment did not affect symptom duration (n = 1793). Patients from whom a bacterial pathogen only was isolated (n = 207) benefited from amoxicillin in that symptom severity (n = 804) was reduced by 0.26 points (95% CI −0.48 to −0.03). The odds of illness deterioration (n = 2024) was 0.24 (95% CI 0.11 to 0.53) times lower from treatment with amoxicillin when both a bacterial and a viral pathogen were isolated (combined infection; n = 198). CONCLUSIONS: Amoxicillin may reduce the risk of illness deterioration in patients with a combined bacterial and viral infection. We found no clinically meaningful benefit from amoxicillin treatment in other subgroups.
has issue date	2017-11-03(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2017.10.032
bibo:pmid	29108950
has license	no-cc
sha1sum (hex)	04925ad6270d4c5ed68218dc052f82470f93e547
schema:url	https://doi.org/10.1016/j.cmi.2017.10.032
resource representing a document's title	Amoxicillin for acute lower respiratory tract infection in primary care: subgroup analysis by bacterial and viral aetiology
has PubMed Central identifier	PMC7128813
has PubMed identifier	29108950
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:04925ad6270d4c5ed68218dc052f82470f93e547#body_text
is schema:about of	named entity 'computer-generated' named entity 'subgroups' named entity 'This' named entity 'patients' named entity 'PRIMARY CARE' named entity 'PLACEBO' named entity 'FOCUSED' named entity 'SUBGROUPS' named entity 'BACTERIAL PATHOGEN' named entity 'NEW OR WORSENING SYMPTOMS' named entity 'OBJECTIVE' named entity 'PROCALCITONIN' named entity 'OF INTEREST' named entity 'AMOXICILLIN' named entity 'NUMBERS' named entity 'VIRAL INFECTION' named entity 'C-REACTIVE PROTEIN' named entity 'USING' named entity 'LRTI' named entity 'RISK OF' named entity 'AFFECT' named entity '804' named entity 'RECEIVE' named entity 'VIRAL PATHOGEN' named entity '0.24' named entity 'HOSPITAL ADMISSION' named entity 'TREATMENT' named entity 'REGRESSION MODELS' named entity 'RANDOM' named entity 'SYMPTOM SEVERITY' named entity 'ANTIBIOTIC' named entity 'PRE-SPECIFIED' named entity 'COMBINED' named entity 'VIRAL' named entity 'OUTCOME' named entity '800' named entity 'METHODS' named entity 'VALUES' named entity 'POTENTIAL' named entity 'REDUCED' named entity 'ELEVATED' named entity 'INFECT' named entity 'ADULTS' named entity 'DETERIORATION' named entity 'TIMES' named entity 'DAYS' named entity 'BENEFIT' named entity 'LOWER RESPIRATORY TRACT INFECTION' named entity 'DID' named entity 'ANALYSIS' named entity 'NOT SUSPECTED' named entity 'POINTS' named entity 'MIXED' named entity 'RANDOMIZED' named entity 'ASSESS' named entity 'BLOOD UREA NITROGEN' named entity 'CONCLUSIONS' named entity 'REDUCE' named entity 'ILLNESS' named entity '2018' named entity 'RANDOMIZED CONTROLLED TRIAL' named entity 'PATIENTS' named entity 'ADULT' named entity 'LOWER' named entity 'ISOLATED' named entity 'INFECTION' named entity 'EITHER' named entity 'CLIN' named entity 'PRESENTING' named entity 'GENERATED' named entity 'CONSECUTIVE DAYS' named entity 'PNEUMONIA' named entity 'RESULTS' named entity 'BACTERIAL' named entity 'THREE TIMES DAILY' named entity 'EFFECTS' named entity '0.11' named entity 'COMPUTER' named entity 'INFECTED' named entity 'FOUND' named entity 'ODDS' named entity 'SECONDARY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software